6-Thioguanine - Efficacy and safety in chronic active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 4, 2003, Pages 503-508

  Herrlinger, K R ^a   Kreisel, W ^b   Schwab, M ^c   Schoelmerich, J ^d   Fleig, W E ^e   Ruhl, A ^f   Reinshagen, M ^g   Deibert, P ^b   Fellermann, K ^a   Greinwald, R ^h   Stange, E F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h Dr Falk Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; MESALAZINE; PREDNISOLONE; STEROID; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSESTHESIA; ECZEMA; ERYTHEMA NODOSUM; FEMALE; GENITAL TRACT INFECTION; HEADACHE; HERPES LABIALIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; MALE; NAUSEA; PANCREATITIS; PHOTOALLERGY; PHOTOTOXICITY; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

6-MERCAPTOPURINE; ADULT; CHRONIC DISEASE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0345549522     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01440.x     Document Type: Article

References (23)

1. Munkhohn P. Langholz E. Davidsen M. Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
2. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2): CD0000 67.
3. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
4. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2): CD000 45.
5. Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 2001; 121: 498-9.
6. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
7. Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102: 439-43.
8. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus mercaptopurine. Cancer Chemother Pharmacol 1998; 42: 266-72.
9. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-9.
10. Kroplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54: 265-71.
11. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
12. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 527-35.
13. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-7.
14. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
15. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
16. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or mercaptopurine. Lancet 1996; 347: 215-9.
17. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
18. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanisnn for interaction with mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
19. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathioprine or mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999; 116: 1505-6.
20. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-64.
21. Key NS, Kelly PM, Emerson PM, Chapman RW, Allan NC, McGee JO. Oesophageal varices associated with busulphanthioguanine combination therapy for chronic myeloid leukaemia. Lancet 1987; 2: 1050-2.
22. Shepherd PC, Fooks J, Gray R, Allan NC. Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine. Br J Haematol 1991; 79: 185-92.
23. Stork LC, Broxson EH, Sather H, et al. Oral 6-thioguanine causes late-onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia. Gastroenterology 2002; 122: 189.